Research paper

Endotrophin is associated with chronic multimorbidity and all-cause mortality in a cohort of elderly women

Line Mærsk Staunstrup\textsuperscript{a,b,*}, Cecilie Liv Bager\textsuperscript{b}, Peder Frederiksen\textsuperscript{b}, Jørn Wulff Helge\textsuperscript{c}, Søren Brunak\textsuperscript{d}, Claus Christiansen\textsuperscript{b}, Morten Karsdal\textsuperscript{b}

\textsuperscript{a} Department of Biomedical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark
\textsuperscript{b} Nordic Bioscience, DK-2730 Herlev, Denmark
\textsuperscript{c} Center for Healthy Aging, Department of Biomedical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark
\textsuperscript{d} Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark

\section*{A R T I C L E  I N F O}

Article History:
Received 29 January 2021
Revised 23 April 2021
Accepted 23 April 2021
Available online xxx

Keywords:
Endotrophin
Chronic disease
Extracellular matrix (ECM)
Fibrosis
Multimorbidity

\section*{A B S T R A C T}

\textbf{Background:} The signalling peptide endotrophin is derived through proteolytic cleavage of the carboxyl-terminal during formation of type VI collagen. It is expressed by most descendants of the mesenchymal stem cells lineage, including adipocytes and fibroblasts, and have been proposed to be a central extracellular matrix hormone associated with several age-related diseases. We aimed to assess the association of endotrophin with chronic disease incidence and death in older women.

\textbf{Methods:} 5,602 elderly Danish women from the observational, prospective cohort: The Prospective Epidemiological Risk Factor (PERF) study were included in the analysis which covered baseline (BL) and follow-up (FU) 14 years later. An elastic net was used to investigate the relative importance of 58 variables to serum endotrophin-levels. 20 chronic diseases were defined on the basis of clinical variables available along with diagnoses extracted from both the National Patient Register, the National Diabetes Register and the Danish Cancer Registry. The cross-sectional associations between endotrophin-levels and these 17 chronic age-related diseases were investigated using logistic regression and a set-analysis explored disease-combinations within multimorbidity. The association of endotrophin with mortality was assessed by Cox proportional hazard models.

\textbf{Findings:} Formation of type III collagen (PRO-C3), age and creatinine-levels were the most influential variables of endotrophin-levels. Several chronic diseases were significantly associated with endotrophin-levels independent of age and BMI including chronic kidney disease (BL OR = 3.7, \( p < 0.001 \); FU OR = 7.9 \( p < 0.001 \)), diabetes (BL OR = 1.5, \( p = 0.0015 \); FU OR = 1.6, \( p = 0.004 \)) and peripheral arterial disease (BL OR = 1.3, \( p = 0.029 \); FU OR = 2.4, \( p < 0.001 \)). Lastly, endotrophin-levels were significantly rising with number of morbidities \( (p < 0.001) \) and a predictor of death after adjusting for age and BMI (BL HR=1.95; FU HR = 2.00).

\textbf{Interpretation:} Endotrophin was associated with death and increased with number of morbidities. Endotrophin may be a central hormone of fibroblast that warrant investigation and possible targeted intervention in several chronic diseases.

© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

\section*{Introduction}

There are more than 40 age-related chronic diseases associated with elevated levels of extracellular matrix (ECM) turnover [1]. This account for more than 50% of deaths in the western world and include cardiovascular, respiratory, dermatological, nephrological and gastrointestinal diseases [2]. Fibroblasts and activated myo-fibroblasts are central components in the progression of these diseases, where they lead propagation of ECM expansion, the interstitial fibrosis, in all organs [3].

Fibroblasts and other mesenchymal descendants produce ECM proteins that are altered during progression of most chronic diseases. Recently, it has been discovered that the altered ECM is not only a consequence but also a driver of some diseases [4]. During remodeling of the ECM, fragmented peptides are released into the circulation. Some of these peptides harbours cryptic sites with novel function such as regulation of cell growth, differentiation, and angiogenesis [5,6]. Endostatin and tumstatin, fragments of type XVIII and IV collagen, are examples of such peptides.

Disclosure summary: CBA and MK are employed at Nordic Bioscience. MK and CC hold stocks in Nordic Bioscience.

\* Corresponding author at: Herlev Hovedgade 207, 2730 Herlev, Denmark.

E-mail address: lms@nordicbio.com (L.M. Staunstrup).

https://doi.org/10.1016/j.ebiom.2021.103391

2352-3964/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Another example of a signalling peptide is endotrophin which is located in the pro-peptide of the type VI alpha 3 chain [7]. During formation of type VI collagen, the carboxyl-terminal (C5) domain is cleaved off. Further processing of the C5 domain generates the signalling fragment endotrophin that can be released into the circulation and quantified by the PRO-C6 assay [8]. Endotrophin is expressed by most cells from mesenchymal stem cells lineage, including adipocytes and fibroblasts [9], and thus, may possibly be a central ECM hormone associated with many chronic fibro-inflammatory disorders.

In animal models, endotrophin has been shown to be involved in several biological processes, such as fibrosis, inflammation, angiogenesis, insulin resistance and epithelial-mesenchymal transition (EMT) [10,11]. In humans, endotrophin has been linked to chronic kidney disease (CKD) [12,13], breast cancer [14], chronic obstructive pulmonary disease (COPD) [15,16], diabetes [17,18] and death [19]. However, the exact functions of endotrophin in humans and the complete picture of the chronic diseases linked to endotrophin remain unknown.

Using a data-driven approach we aimed to get a better understanding of endotrophin's role in chronic age-related diseases in the Prospective Epidemiological Risk Factor (PERF) study (n = 5602). The PERF cohort is a study of elderly women that was followed for 14 years and has been linked to several Danish health registries. Accordingly, we examined the association of endotrophin with 58 clinical parameters, 17 chronic age-related diseases, number of morbidities and death at baseline and 14 years later at follow-up.

**Methods**

**Study design**

The Prospective Epidemiological Risk Factor (PERF) study, established in 1999–2001 (baseline), took aim at developing the understanding of age-related diseases in elderly women [20]. Women who previously participated in clinical randomized prevention trials or had been screened for inclusion in clinical prevention trials (n = 8875) at the Center for Clinical and Basic Research (CCBR) were invited to participate in the PERF study. A total of 5855 Danish elderly women (avg. age 71 yrs.) were enrolled in PERF at baseline and approximately 14 years later (yr. 2013–2014) a follow-up study was established when 2103 women (avg. age 81 yrs.) were re-examined. The study has been described in detail elsewhere [21].

**Baseline and follow-up investigations**

The participants completed interviews with a doctor or a nurse covering questions related to demographics, lifestyle, and medical history both at baseline and follow-up. A medical physical exam included DXA-scanning at baseline and standard body shape measures at follow-up. Furthermore, a cognitive test resulting in a range of cognitive scores was performed at both time points.

**Endotrophin measurements**

All subjects provided fasting blood samples both at baseline and follow-up and serum was stored at −80 °C before the biomarkers were measured blinded in a CAP-certified laboratory. Serum endotrophin was measured in November-December 2016 after confirming the stability of the samples by running seven consecutive freeze-thaw cycles with no significant variation detected. Further, a three-year stability test was performed by measuring the same sample with a one-year interval. A complete description of all biomarkers including measuring methods and variables used in the analysis is shown in table S1.

**Linkage to disease and death registries**

In Denmark, every citizen has a unique personal subject identification number (CPR-number) which enabled matching of the women to various electronic health- and death-registries at the level of individuals. Health information used for this study was derived from: The Danish National Patient Register [22], the National Danish Causes of Death Registry [23], the Danish Adult Diabetes Registry [24], and the Danish Cancer Registry [25] covering the time span of the PERF study and time before baseline (pre-baseline). The national registries used in this analysis have previously been validated [26–29].

**Disease phenotypes and multimorbidity**

Based on electronic health records, relevant biomarkers, medical work-up and questionnaire-information, 17 different disease
phenotypes were defined (Table 2). The exact definitions used for the phenotypic disease-grouping is available in table S2. These 17 diseases were selected with the aim of covering a wide range of chronic fibro-inflammatory disorders in the elderly [30].

The disease phenotypes were evaluated at baseline and follow-up for each woman resulting in two binary disease-matrices. The baseline definition covers the time before baseline and up until 1 year after baseline, and follow-up covers pre-baseline up until 14 years after baseline. Data gathered at baseline was used for the baseline definition, whereas the follow-up definition was based on data collected both at baseline and follow-up.

Multimorbidity was evaluated at each time point as a count of number of diseases estimated by adding the disease-phenotypes for each woman.

Inclusion criteria

Women with electronic health records available from the Danish National Patient Register were included in the analysis (Fig. 1).

The prospective design of the PERF study unavoidably results in a healthy bias of the women participating in the follow-up study. A thorough investigation of endotrophin-levels and BMI between the women lost to follow-up and the women participating in the follow-up study has been conducted to ensure no systematic bias. The reason for loss to follow-up was most dominantly death (53.5%) and geographical distance (26.4%) followed by unknown/other reasons (12.7%) (Fig. 1). We found that women not participating in the follow-up study in general were older. We also found in an ANCOVA analysis adjusted for age and analysis-time that neither BMI nor endotrophin levels at baseline were significantly different between the women participating in the follow-up study and the women that were lost to follow-up (independent of reason for exclusion) (Figure S1).

Statistical analyses

Endotrophin and variable importance

The relative importance of each variable to the levels of endotrophin in elderly women was investigated with an elastic net applying 5-fold cross-validation repeated 20 times. Endotrophin level was the outcome of the model and all variables included in the model are listed in table S1. The caret R-package was used for the elastic net [31]. We chose to use penalized regression because the number of variables was high with the risk of collinearity. Dummy variables were generated for all categorical variables. Continuous variables were firstly normalized and further standardized. For the normalization, all values higher or lower than 1.5 times the inter quartile range (IQR) were set to this upper/lower limit, respectively. Data was standardized to a mean of 0 and a standard deviation of 1. The coefficients of the final model were extracted and used for variable importance assessment.

Endotrophin and chronic age-related disease

A logistic regression model was fitted to investigate the association between endotrophin and disease phenotypes (Table S2) both at baseline and follow-up. All regressions were adjusted for age and BMI at baseline and follow-up, respectively. Furthermore, at baseline the analysis was adjusted for analysis-time. Endotrophin was log2-transformed prior to analysis. Finally, all p-values were adjusted using the method by Benjamini & Yekutieli to target a false discovery rate of 5%. All odds ratios reported corresponds to a doubling of endotrophin-levels.

Endotrophin and multimorbidity

To investigate the association between endotrophin-levels and multimorbidity an aggregated disease-sum was derived for each woman. This was done by adding the number of diseases observed for each woman. Again, we did this at the two different time points. We excluded the multimorbidity-groups with less than 20 women observed and plotted the median endotrophin level ± Q1/Q3 for each group. Tests for linear or quadratic trend were performed using linear regression.

To visually represent which disease phenotypes were prevalent within each multimorbidity-group, a stacked barplot showing the percentage distribution of each disease phenotype was generated.

The specific disease-combinations within each multimorbidity-group was further investigated with a set analysis. All sets presenting with more than 20 women were visualized in an UpSet plot using the
ComplexHeatmap library in R. The endotrophin-levels observed for each disease-combination was visualized with a barplot showing the median ± Q1/Q3.

**Endotrophin and all-cause mortality**

Cox proportional hazards models were used to evaluate the relationship between endotrophin and all-cause mortality up to 1 year after the endotrophin measurement at baseline and follow-up. Both models were adjusted for BMI and age for the two time points respectively. Endotrophin-levels were log2-transformed prior to analysis. The cubic splines showed that the data was linearly associated. Further, MMP disease phenotypes were in accordance with what have been observed in other studies [34,35], and the relatively small delta between the two timepoints is expected as endotrophin seems to impact the microenvironment locally.

### Disease phenotypes

For this study 17 different age-related inflammatory and fibroproliferative chronic diseases were defined (Table 2) based on electronic health records (specific ICD10 codes), relevant biomarkers, and questionnaire-information. The prevalence of the chronic diseases is shown in Table 2. Generally, the percentage of women with diseases increased from baseline to follow-up, most likely due to higher age. The disease phenotype observed with the highest prevalence, both at baseline and follow-up, was hypertension with 37.99% and 66.57% women affected at the respective time-points. The rarest observed disease phenotype was respiratory cancer with 0.43% of the women at baseline being sick and 1% at follow-up. These percentages are in line with what would be expected for an elderly population [36–38].

### Ranking of variable importance to endotrophin

A variable importance analysis using an elastic net was conducted with the aim of exploring which variables were associated with endotrophin. This was done both for endotrophin measured at baseline (58 variables) and at follow-up (46 variables) (Table S1). The top 20 variables for each analysis are shown in Fig. 2. The analysis implicated the fibrotic biomarker PRO-C3, creatinine and age as the variables with largest impact on endotrophin levels. Further, MMP levels with largest impact on endotrophin levels. Further, MMP

### Ethics

The PERF study was carried out in accordance with the protocol approved by the Research Ethics Committee of Copenhagen County, Viborg and Northern Jutland, Denmark (KA 99070gm) and in conformance with Good Clinical Practice and the Helsinki Declaration II. Written informed consent was obtained from all participants.

### Funding

The funder of the PERF study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

### Results

#### Cohort characteristics

There were 5602 elderly women at baseline with available electronic health records, and 2094 women in the follow-up study (Fig. 1). No systematic bias was found between the women lost to follow-up and the women participating in the follow-up study. Both baseline and follow-up characteristics are summarized in Table 1. On average the women were 70.16.6 years old at baseline and 81±6.1 years old at follow-up. The mean BMI of 26 did not change between baseline and follow-up. The median endotrophin levels rose from 8.3 ng/ml to 10.1 ng/m from baseline to follow-up. These levels of endotrophin are in accordance with what have been observed in other studies [34,35], and the relatively small delta between the two timepoints is expected as endotrophin seems to impact the microenvironment locally.

### Table 1

Baseline and follow-up characteristics for the studied women. IQR: Interquartile range.

| Characteristics                        | Baseline | Follow-up |
|----------------------------------------|----------|-----------|
| Age (years)                            | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 71.0 ± 10.0 (5602) | 81.0 ± 9.2 (2094) |
| BMI (kg/m²)                            | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 26.0 ± 5.3 (53966) | 26.0 ± 6.0 (16050) |
| Fat % (from DXA)                       | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 41.0 ± 9.5 (5060) | - |
| Waist Circumference                    | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | -        | 86.0 ± 16 (1951) |
| HOMA-IR                                | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 82.0 ± 5.4 (53708) | 92.0 ± 7.5 (2044) |
| Systolic blood pressure (mm HG)        | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 150.0 ± 33.0 (54400) | 140.0 ± 27.0 (1973) |
| Diastolic blood pressure (mm HG)       | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 81.0 ± 16.0 (54422) | 80.0 ± 14.0 (1973) |
| Education                              | N = 5602 | N = 2094  |
| High school/University, n/ total (%)   | 1594/5594 (28%) | Same as baseline |
| Smoking                                | N = 5602 | N = 2094  |
| Current/Former, n/ total (%)          | 2957/5597 (53%) | 1035/2094 (49%) |
| Never, n/ total (%)                   | 2640/5597 (47%) | 1059/2094 (51%) |
| Alcohol                                | N = 5602 | N = 2094  |
| < 7 units/week, n/ total (%)          | 2491/5594 (44%) | 85/1980 (4%) |
| ≥ 7 units/week, n/ total (%)          | 3103/5594 (55%) | 1895/1980 (90%) |
| Recreational walking (min. 10 min)    | N = 5602 | N = 2094  |
| ≥ 5 times/week, n/total (%)           | 4006/5597 (72%) | 1087/1971 (52%) |
| < 5 times/week, n/ total (%)          | 1591/5597 (28%) | 884/1971 (42%) |
| Exercise habits                        | N = 5602 | N = 2094  |
| ≥ 1 time/week, n (%)                  | 3838/5596 (69%) | 1295/1969 (62%) |
| < 1 time/week, n (%)                  | 1758/5596 (31%) | 674/1969 (32%) |
| Endotrophin (ng/ml)                    | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 8.3 ± 1.5 (33718) | 10.1 ± 3.9 (2044) |
| Lymphocyes (%)                         | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 33.0 ± 11.0 (51400) | 31.0 ± 12.0 (2082) |
| Neutrophils (%)                        | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 59.0 ± 11.0 (51400) | 56.0 ± 12.0 (2082) |
| Cholesterol (mmol/l)                   | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 6.3 ± 1.4 (54282) | 5.5 ± 1.5 (2085) |
| Triglycerid (mmol/l)                   | N = 5602 | N = 2094  |
| Median ± IQR (n)                       | 1.2 ± 0.7 (54227) | 1.1 ± 0.6 (2085) |
degraded type VI collagen (C6M), triglyceride, haemoglobin, albumin, total fat and waist circumference ranked high.

Disease phenotypes associated with endotrophin

To quantify the association between endotrophin and different chronic age-related diseases a logistic regression was run for each of the disease phenotypes, both at baseline and follow-up (Fig. 3). All analyses were adjusted for age and BMI and further FDR-corrected. Chronic kidney disease showed to be the phenotype with the strongest association to endotrophin both at baseline and follow-up [(BL; \( p_{adj} = 4.72 \times 10^{-55}, OR = 5.7 \)), (FU; \( p_{adj} = 3.14 \times 10^{-39}, OR = 7.9 \))]. Also, a range of other chronic diseases were significantly associated with endotrophin levels: diabetes, rheumatic disease, peripheral arterial disease, Ischemic heart disease, chronic liver disease and gastrointestinal cancer. Inflammatory bowel disease and chronic pulmonary disease were not significantly associated with endotrophin levels at baseline, but the association became significant at follow-up.

Endotrophin and multimorbidity

The association between multimorbidity and endotrophin was evaluated by plotting the number of diseases for each woman against endotrophin levels at baseline and follow-up, respectively (Fig. 4). We observed rising endotrophin levels with increased number of chronic diseases. This was true both at baseline and follow-up and significant in tests for linear or quadratic trend (all \( p < 0.001 \)) across the number of diseases. Generally, we saw overall higher endotrophin levels when measured at follow-up, where the age on average was 11 years higher. To ensure age not being the underlying reason for higher endotrophin levels in the groups with more multimorbidity, each multimorbidity-group was stratified into age-groups and

Table 2
Prevalence of women with chronic disease phenotypes stratified by disease-group and timepoint.

| Group             | Disease phenotypes                                  | Baseline N = 5602 (%) | Follow-up N = 2094 (%) |
|-------------------|-----------------------------------------------------|------------------------|------------------------|
| **Brain**         | Alzheimer's/Dementia                               | 106 (1.89%)            | 179 (8.55%)            |
|                   | Gastrointestinal Cancer                            | 91 (1.62%)             | 114 (5.44%)            |
|                   | Respiratory Cancer                                 | 24 (0.43%)             | 21 (1%)                |
|                   | Breast Cancer                                      | 213 (3.80%)            | 165 (7.83%)            |
|                   | Female genital organ cancer                        | 128 (2.29%)            | 72 (3.44%)             |
| **Cardiovascular**| Hypertension                                       | 2128 (37.99%)          | 1394 (66.57%)          |
|                   | Ischemic Heart Disease                             | 310 (5.53%)            | 277 (13.23%)           |
|                   | Peripheral Arterial Disease                        | 444 (7.93%)            | 149 (7.12%)            |
|                   | Congestive Heart Failure                           | 116 (2.07%)            | 188 (8.98%)            |
|                   | Cerebrovascular Diseases                           | 293 (5.23%)            | 351 (16.76%)           |
|                   | Atrial Fibrillation                                | 204 (3.64%)            | 292 (13.94%)           |
| **Musculoskeletal**| Rheumatic Disease                                  | 278 (4.96%)            | 227 (10.84%)           |
|                   | Osteoarthritis                                     | 1934 (34.52%)          | 1262 (60.27%)          |
|                   | Osteoporosis                                       | 1291 (23.03%)          | 615 (29.37%)           |
| **Digestive**     | Inflammatory Bowel Disease                         | 77 (1.37%)             | 96 (4.58%)             |
|                   | Chronic Kidney Disease                             | 1054 (18.81%)          | 481 (22.97%)           |
|                   | Chronic Liver Disease                              | 121 (2.16%)            | 90 (4.3%)              |
| **Lung**          | Chronic Pulmonary Disease                          | 326 (5.82%)            | 387 (18.48%)           |
| **Metabolic**     | Hyperlipidaemia                                    | 1168 (20.85%)          | 618 (29.51%)           |
|                   | Diabetes                                            | 401 (7.16%)            | 361 (17.24%)           |

Fig. 2. Variable importance plots showing the top 20 most significant variables in relation to endotrophin. PRO-C2: formation of type II collagen; PRO-C3: formation of type III collagen; C1M: MMP degraded type I collagen; C3M: MMP degraded type III collagen; C6M: MMP degraded type VI collagen; CRPM: MMP degraded CRP (C-reactive protein); BMD: bone mineral density; VICM: MMP degraded and citrullinated vimentin; HOMA-IR: homeostatic model assessment of insulin resistance; mixed cells: monocytes, eosinophils, and basophils; CFT: The category fluency test with animal naming; TAU: Adam degraded TAU; GGT: Gamma-Glutamyl Transpeptidase.
the endotrophin levels were investigated. We saw that the endotrophin levels were increasing with number of diseases independent of age (Figure S2). The prevalence of diseases within each multimorbidity-group was represented in a stacked barplot, and here we saw that hypertension and osteoarthritis were highly represented in the groups with low multimorbidity.

Hyperlipidaemia and chronic kidney disease maintained a similar percentage prevalence with rising number of morbidities, whereas diabetes, ischemic heart disease, peripheral arterial disease and congestive heart failure rose in the overall prevalence.

To investigate the relationship between multimorbidity and level of endotrophin we performed a set-analysis and examined the disease-combinations presenting with more than 20 women (Fig. 5). We saw that CKD, diabetes and hypertension were among the diseases most represented in the disease-combinations with highest endotrophin-levels. As a limit of 20 women was applied, the disease-combinations presented in Fig. 5 consist predominantly of diseases that has a high prevalence in the population.

All-cause mortality in relation to endotrophin

As endotrophin levels were associated with number of morbidities after adjusting for age and BMI we further hypothesized that endotrophin levels were associated with all-cause death after adjustment for age and BMI. We have previously seen that endotrophin was associated with death up to 15 years after baseline in the PERF cohort [19]. To re-evaluate if the same picture was seen 1 year after baseline and at follow-up we performed a sub-analysis. The association of endotrophin-levels with all-cause mortality after 1 year was evaluated both at baseline and follow-up with a Cox regression analysis with time since the endotrophin measurement as the underlying time scale and adjustment for age and BMI. Endotrophin was a significant predictor of all-cause mortality both at baseline and follow-up (BL: HR = 4.66, 95% CI = 2.35–9.26; p < 0.0001; FU: HR = 3.53; 95% CI = 1.88–6.60; p < 0.0001). Hazard ratios correspond to a two-fold increase in endotrophin levels. At each time points the model including age, BMI and endotrophin were significantly predicting mortality

---

**Fig. 3.** Association plot for endotrophin and disease phenotypes showing FDR adjusted p-values. The black line depicts the target FDR level of 0.05, dotted line represents a target FDR of 10%.
with concordance index (c-index) of 0.82 and 0.81, indicating strong predictive models (Fig. 6).

**Discussion**

The ECM is produced mainly by fibroblasts and was previously thought of only as a structure that added stability and organization to cells and tissue, however it is now recognized that the ECM also provides signalling cues that regulate cell differentiation, growth, and migration [5,6]. One such example is the procollagen fragment endotrophin (PRO-C6) which is released by proteolysis during formation of type VI collagen. In its cleaved form it has been shown to have signalling abilities in animal models and been linked to development of chronic diseases in humans [10,11,17,39]. In the present study we investigated the association between endotrophin and chronic disease burden in a cohort of 5602 Danish elderly women. To our knowledge, we are the first to investigate the association between endotrophin and disease in a large clinical cohort. Our study found
that the variables most associated with endotrophin was the fibrotic fibroblast biomarker PRO-C3 together with creatinine and age. Furthermore, we showed that endotrophin, independent of age and BMI, was significantly associated with 9 age-related chronic diseases out of 17 studied at two different time-points, including chronic kidney disease, diabetes, peripheral arterial disease, and rheumatic disease. Additionally, we saw that endotrophin levels increased significantly with number of morbidities beyond what could be explained by age alone. Lastly, we found endotrophin-levels to be a significant predictor for all-cause mortality both 1 year after baseline and follow-up. Together the findings highlight the role of endotrophin in progression of age-related inflammatory and fibroproliferative diseases.

During aging, the ECM is altered leading to stiffer and mechanically weaker tissues, which compromise the ECM organization and thereby help promote development of chronic age-related diseases [40]. This phenomenon is further accelerated by obesity that can lead to an unbalanced remodelling of the ECM in adipose tissue due to metabolic dysfunction. It has been proposed that systemic insulin resistance induced by obesity is closely related to fibrosis and inflammation in adipose tissues [11,41]. Recent studies in mice have shown that endotrophin is related to a variety of biological processes such as fibrosis, inflammation, and insulin-resistance. Sun et al. showed in high-fat diet mice that overexpression of endotrophin plays a critical role in insulin resistance through stimulation of chronic inflammation and fibrosis under both acute and chronic settings [11]. Further studies in humans have substantiated this link. Yoldemir et al. found endotrophin significantly associated with insulin resistance and upregulated in overweight individual [41] and several clinical studies have found endotrophin elevated in fibrotic conditions where it is produced by fibroblasts [12,13,15,16]. This correlates well with our findings where endotrophin levels were associated with both fibrotic and obesity-related clinical variables and chronic diseases. We found endotrophin levels associated with triglycerides, total fat, HOMA-IR, waist circumference as well as the fibrosis biomarker PRO-C3 that reflect type III collagen deposition [42–44]. We also found endotrophin associated with several chronic conditions associated with obesity and fibrosis such as diabetes, ischemic heart disease, CKD and chronic liver disease. These results highlight the pro-fibrotic properties of endotrophin and underlines its relevance in chronic age-related inflammatory and fibro-proliferative diseases.

The association between endotrophin and several different chronic age-related diseases led to further investigations of the relationship between endotrophin and multimorbidity, defined as the coexistence of multiple chronic diseases within an individual [45]. We found that endotrophin levels rose significantly with the number of co-existing diseases both at baseline and follow-up, even after stratifying by age. Although it is not possible, due to the study-design, to conclude on causality, the results presented in this clinical study, concur with the suggested pro-fibrotic roles in animal models [11], and support that endotrophin is a driving factor for progression of chronic diseases and rising number of morbidities. This is further supported by the association between endotrophin and death that we observed in this study and by a recent publication by Lee et al. showing that endotrophin acts as an accelerator of disease in a mouse model of non-alcoholic liver disease (NAFLD) [46].

As expected, we found, in a set-analysis, that the diseases represented in a disease-combination influenced the endotrophin-levels. Generally, we saw that disease-combinations containing CKD had higher endotrophin levels compared to other combinations. This was not surprising as we found endotrophin significantly associated with CKD both at baseline and follow-up in a logistic regression adjusted for age and BMI. Furthermore, we found creatinine to be the second highest ranked variable impacting endotrophin at both time points. This is in line with several studies that have previously investigated the association between endotrophin and CKD. In a study from 2017 [13] Rasmussen et al. showed that high values of endotrophin were significantly associated with CKD disease progression and the same year, Stribos et al. [47], showed that endotrophin was able to reflect CKD severity in renal transplant patients. The same conclusion was made in a study with type 1 diabetes patients [39], where endotrophin was found to be an independent predictor of decline in estimated glomerular filtration rate (eGFR).

Understanding the relationship between endotrophin and development of single and multiple chronic age-related diseases might provide the key for a better understanding of how the ECM can promote diseases. Accumulating evidence suggests an imbalance of the ECM to be associated with disease progression. Despite fibroblasts and the altered ECM playing a central role in many chronic diseases, no fibroblast biomarkers are currently used in standard clinical practice. It remains an underappreciated topic of clinical chemistry as to how central fibroblast biological events contribute to multimorbidity and death. Measuring serological endotrophin may therefore provide information of the fibroblast component of chronic diseases and help monitor progression of chronic diseases in the elderly and guide preventive actions to decrease multimorbidity and death.

This study had several strengths and limitations. The limitations include the fact that some diseases were less prevalent causing problems especially when grouping the data by disease-combinations.
This was the primary reason for evaluating multimorbidity as the sum of diseases, though one should be aware that a particular combination of specific diseases may have a greater impact on health compared to others. The chronic diseases in this article were defined using a combination of information from Danish registries, biomarker measures, questionnaire answers and other clinical variables (Table S2) and were thereby not directly validated by a medical doctor. Also, the study-design of this large cohort made it impossible to conclude on causality. Furthermore, the data only included Danish elderly women, and may therefore not be generalizable to the general population. The strengths of this study include the large number of endotrophin measurements in humans at two time points and the possibility to link this with comprehensive data on disease history combined with a large number of clinical variables.

In conclusion, this study suggests that endotrophin is associated with the degree of multimorbidity and death in elderly women. Measuring endotrophin, in addition to standard clinical chemistry, may provide information on fibroblast activity and help monitor multimorbidity and death in the elderly.

Declaration of Competing Interest
CLB, CC, LMS, MK, PF report grants from the Danish Research Foundation (Den Danske Forskningsfond) during the conduct of the study. CLB and MK report personal fees from ProScion A/S. CLB, MK and PF report personal fees from Nordic Bioscience A/S. CLB, CC and MK have stock in Nordic Bioscience A/S. CC reports being a board member of Nordic Bioscience A/S. CC and SB report being a board member of ProScion A/S. JWH has nothing to disclose. LMS reports ownership in Intomics A/S, Hoba Therapeutics A/S and Lundbeck A/S.

Acknowledgments
We acknowledge the Danish Research Foundation (Den Danske Forskningsfond) for funding the PERF I and PERF II studies. SB acknowledges support from the Novo Nordic Foundation (Grant NNF14CC0001).

Contributors
LMS, CLB, JWH, CC and MK contributed to the conception and design of the study. CLB, CC, MK and LMS administrated the project and had responsibility for the management and coordination of the project. PF, LMS, SB and CLB advised on all statistical aspects and interpreted the data. LMS performed the statistical analysis. LMS and CLB drafted the manuscript. LMS, CLB, MK, CC, SB, PF and JWH reviewed the manuscript and approved the final version to be published. LMS, CBL, MK and PF had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. CC and MK conceptualized the PERF cohort and provided the study material. CC, MK, SB and JWH constituted mentorship. LMS generated and preprocessed all plots and visualization.

Data sharing
The original data of the Prospective Epidemiological Risk Factor study and the linkage data from various registries are currently stored at Nordic Bioscience. Access to this database will be granted, on condition that researchers have appropriate ethical permission and sign the appropriate Material Transfer Agreement form.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.ebiom.2021.103391.

References
[1] Karsdal MA, Krarup H, Sand JM, Christensen PB, Gerstoft J, Leeming DJ, et al. Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - Early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 2014;40(1):53–71.
[2] Karsdal MA, Kraus VB, Shevell D, Bay-Jensen A-C, Schattenberg J, Surabattula R, et al. Profiling and targeting connective tissue remodeling in autoimmunity - a novel paradigm for diagnosing and treating chronic diseases. Autoimmun Rev 2016;15(11):1301–8. Available from: doi:10.1016/j.autrev.2015.12.016.
[3] Karsdal MA, Manon-Jensen T, Genovese F, Kristensen JH, Nielsen MJ, Sand JM, et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol - Gastrointest Liver Physiol 2015;308(10):G807–30.
[4] Herrera J, Henke CA, Bitterman PB. Extracellular matrix as a driver of progressive fibrosis. J Clin Invest 2018;128(1):45–53.
[5] Karsdal MA, Nielsen MJ, Sand JM, Henrikson K, Genovese F, Bay-Jensen A-C, et al. Extracellular Matrix remodeling: the common denominator in connective tissue diseases. Assay Drug Dev Technol 2013;11(2):70–92. Available from http://online.liebertpub.com/doi/abs/10.1089/adt.2012.474.
[6] Hynes RO. The extracellular matrix : not just pretty fibrils. Science (80-) 2009;326:1216–20 November.
[7] Karsdal M, Leeming DJ, Henrikson K, Bay-Jensen A-C. Biochemistry of collagen, laminins and elastin. Structure, function and biomarkers. Academic Press; 2016.
[8] Sun S, Karsdal MA, Bay-Jensen AC, Sørensen MG, Zheng Q, Dziegieł MH, et al. The development and characterization of an ELISA specifically detecting the active form of cathepsin K. Clin Biochem 2013;46(15):1601–6. Available from: doi:10.1016/j.clinbiochem.2013.04.012.
[9] Juhl P, Bondesen S, Hawkins CL, Karsdal MA, Bay-Jensen AC, Davies MJ, et al. Dermarobotics Matrix remodeling: different extracellular matrix profiles induced by TGF-β, PDGF and IL-6 in a model for skin fibrosis. Sci Rep 2020;10(1):1–10. Available from: doi:10.1038/s41598-020-74179-6.
[10] Park J, Scherer PE. Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Invest 2012;122(11):4243–56.
[11] Sun K, Park J, Gupta OT, Holland WL, Auerbach P, Zhang N, et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun 2014;5:3485.
[12] Fenton A, Jesky MD, Fero C, Sørensen J, Karsdal MA, Cockwell P, et al. Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease. PLoS One 2017;12(4):1–14.
[13] Rasmussen D, Fenton A, Jesky M, Fero C, Boor F, Tepel M, et al. Urinary endotrophin predicts disease progression in patients with chronic kidney disease. Sci Rep 2017.
[14] Bu D, Crewe C, Kusminski CM, Cordillo R, Ghaben AL, Kim M, et al. Human endotrophin as a driver of malignant tumor growth. JCI Insight 2019;4(9):1–16.
[15] Rannou SR, Langholm LL, Karsdal MA, Manon-Jensen T, Tal-Singer R, Miller RE, et al. Endotrophin, an extracellular hormone, in combination with neoptoipeptide markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort. Respir Res 2020;21:202. NLM (Medline).
[16] Billiet AR, Karsdal MA, Sand JM, Leeming DJ, Roberts M, White W, et al. Biomarkers of extracellular matrix turnover are associated with emphyesma and eosinophilic–bronchitis in COPD. Respir Res 2017;18:22.
[17] Karsdal MA, Henrikson K, Genovese F, Leeming DJ, Nielsen MJ, Rius BJ, et al. Serum endotrophin identifies optimal responders to PPAR agonists in type 2 diabetes. Diabetologia 2017;60(1):50–9.
[18] Fronhofer-Moller M, Hansen TW, Rasmussen D, Teglia S, Nielsen SH, Karsdal MA, et al. Marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes. Acta Diabetol 2017;54(6):711–2.
[19] Bager CL, Willumsen N, Christiansen C, Bay-Jensen AC, Nielsen HB, Karsdal MA. Bone and soft tissue turnover in relation to all-cause mortality in postmenopausal women. J Gerontol - Ser A Biol Sci Med Sci 2019;74(7):1098–104.
[20] Neergaard JS, Dragsbæk K, Christiansen C, Bay-Jensen AC, Nielsen HB, Karsdal MA. A marker of type VI collagen formation (PRO-C6) is associated with medullary bone turnover. J Bone Miner Res 2017;32(6):995–1004. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367316/
[21] Frimodt-Møller M, Nielsen MJ, Sand JM, Henrikson K, Genovese F, Bay-Jensen A-C, et al. Extracellular Matrix remodeling: the common denominator in connective tissue diseases. Assay Drug Dev Technol 2013;11(2):70–92. Available from: doi:10.1089/adt.2012.474.
[22] Neergaard JS, Dragsbæk K, Kehlet SN, Hansen HB, Hansen G, Byrjalsen I, et al. Cause of death registry [Internet]. [cited 2020 Sep 9]. Available from: https://www.ssi.dk/media/Indhold/DK-%20dansk/Sundhedsdata%20og-sund柄het-data/Cancerregisteret%20Sundhedssystemet%20Agreement%20on%20Cancerregisteret/Valideringsrapport_Cancerregisteret_English%20abstract.
[23] Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health 2011;39(7):330–3.
[24] Cause of death registry [Internet]. [cited 2020 Sep 9]. Available from: https://www.ssi.dk/media/Indhold/DK-%20dansk/Sundhedsdata%20og-sund柄het-data/Cancerregisteret%20Sundhedssystemet%20Agreement%20on%20Cancerregisteret/Valideringsrapport_Cancerregisteret_English%20abstract.
[25] The Cancer Registry [Internet]. [cited 2020 Sep 9]. Available from: http://www.sciencedirect.com/science/article/pii/S016524941000041X.
[26] The State Serum Institute in Denmark. Validation of The Danish Cancer Registry and selected Clinical Cancer Databases. Web Publ [Internet] 2004;6–7. Available from: https://www.ssi.dk/media/Indhold/DK-%20dansk/Sundhedsdata%20og-sund柄het-data/Cancerregisteret%20Sundhedssystemet%20Agreement%20on%20Cancerregisteret/Valideringsrapport_Cancerregisteret_English%20abstract.
